Redhill Biopharma Ltd (RDHL) 12.69 $RDHL
RedHill Biopharma Announces Closing of Public Offering of Its American Depository Shares
GlobeNewswire - Fri Feb 13, 9:19AM CST
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" or the "Company"
, an Israeli biopharmaceutical company primarily focused on late clinical-stage, proprietary, orally-administered drugs for inflammatory and gastrointestinal diseases, including gastrointestinal cancers, is today announcing the closing of its previously announced underwritten public offering of 1,000,000 American Depository Shares ("ADSs" , each representing ten of its ordinary shares, at an offering price of $12.50 per ADS. RedHill has also granted the underwriters a 30-day option to purchase up to 150,000 additional ADSs to cover over-allotments, if any.
RDHL: 12.69 (+0.04)
RedHill Biopharma to Present at the Life Sciences Israel(TM) 2015 3rd Annual International Partnering Conference
GlobeNewswire - Thu Feb 12, 7:02AM CST
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" , an Israeli biopharmaceutical company primarily focused on late clinical-stage, proprietary, orally-administered drugs for inflammatory and gastrointestinal diseases, including gastrointestinal cancers, today announced that Dror Ben-Asher, RedHill's Chief Executive Officer, will be presenting at the Life Sciences Israel 2015 3 Annual International Partnering Conference on Thursday, February 19, 2015, at 11:30am IST, at the Dan Panorama Hotel, in Tel-Aviv, Israel.
RDHL: 12.69 (+0.04)
RedHill Bio prices offering
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 9:43AM CST
RDHL: 12.69 (+0.04)
RedHill Biopharma Prices Public Offering of Its American Depository Shares
GlobeNewswire - Tue Feb 10, 8:08AM CST
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" or the "Company" , an Israeli biopharmaceutical company primarily focused on late clinical-stage, proprietary, orally-administered drugs for inflammatory and gastrointestinal diseases, including gastrointestinal cancers, today announced pricing of its previously announced underwritten public offering of 1 million American Depository Shares ("ADSs" , each representing ten of its ordinary shares, at an offering price of $12.5 per ADS.
RDHL: 12.69 (+0.04)
17 Healthcare Companies To Consider Based On Patent Dynamics And IP/Patent Indexes
Innovalpha - Seeking Alpha - Tue Feb 10, 8:08AM CST
Introduction We will present here a few healthcare stocks that have been recently selected by our IP models. As already explained in our SA article " Patent Dynamics And Stock Performance ", Innovalpha has developed proprietary IP and...
SGYP: 2.98 (unch), INSM: 17.40 (+0.69), RNN: 0.75 (+0.01), ZSPH: 46.77 (+3.42), RDHL: 12.69 (+0.04), ASPX: 65.76 (+2.76), ACUR: 0.55 (+0.01), XNPT: 6.69 (-0.21), SPNC: 33.69 (-0.06), CORI: 7.00 (-0.05), SAGE: 41.03 (-0.07), EBIO: 10.13 (+0.05), HAE: 42.94 (-0.59), JAZZ: 169.69 (+6.89), ICPT: 209.12 (+7.12), NVDQ: 15.12 (+0.51)
RedHill Biopharma initiates equity offering
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 3:10PM CST
RDHL: 12.69 (+0.04)
RedHill Biopharma Announces Proposed Public Offering of Its American Depository Shares
GlobeNewswire - Mon Feb 09, 3:00PM CST
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" or the "Company" , an Israeli biopharmaceutical company primarily focused on late clinical-stage, proprietary, orally-administered drugs for inflammatory and gastrointestinal diseases, including gastrointestinal cancers, today announced that it intends to offer its American Depository Shares ("ADSs" , each representing ten of its ordinary shares, in an underwritten public offering. RedHill also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the ADSs offered to the public to cover over-allotments, if any. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
RDHL: 12.69 (+0.04)
Global Migraine Drugs Market 2015-2019 with Abbott, Allergan, Eisai, Endo, GlaxoSmithKline, Impax Laboratories & Pfizer Dominating
M2 - Fri Feb 06, 8:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/s55lbq/global_migraine) has announced the addition of the "Global Migraine Drugs Market 2015-2019" report to their offering. The Global Migraine Drugs market to grow at a CAGR of 3.54% over the period 2014-2019. Migraine is a complex neurological medicial condition characterized by a severe headache. The headache is often accompanied by nausea, vomiting, and extreme sensitivity to light and sound. Given their hormonal fluctuation, women are more susceptible to have migraine than men. Anti-migraine drugs are the therapeutic agents to be used against migraine. Treatment includes painkillers, anti-inflammatory painkillers, anti-sickness medicines, and triptan medicines. The development of new drugs such as CGRP receptor antagonist and Botox is one of the major trends emerging in the market. Moreover, the demand for anti-migraine drugs is expected to grow further driving the market growth. According to the report, an increased prevalence of migraine is one of the main drivers of the market. Migraine is highly prevalent worldwide and affects people irrespective of their age, race, level of income, and geographical location. Further, the report states that the high cost of drugs is one of the main challenges faced by the market. Regardless of the numerous benefits, the high cost of drugs impedes acceptability among patients. The manufacturing process of a generic involves the use of the right equipment, expertise, and the ability to demonstrate to the FDA that the generic is absorbed through the skin in quantities that are identical to that of the branded drug. This cycle leads to an increase in the manufacturing costs, thereby increasing the overall cost of the drug. Key Vendors - Abbott - Allergan - Eisai - Endo - GlaxoSmithKline - Impax Laboratories - Pfizer Other Prominent Vendors - Almirall - Amgen - AstraZeneca - Boehringer Ingelheim - Eli Lilly - IntelGenx Technologies - Johnson & Johnson - Nautilus - OptiNose - RedHill Biopharma - Zogenix Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Migraine Pipeline Snapshot - Migraine Pipeline Assessment - Market Segmentation by Therapeutic Class - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/s5...l_migraine
IPXL: 39.51 (+0.69), AGN: 229.49 (+1.87), JNJ: 99.62 (+1.18), RDHL: 12.69 (+0.04), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99)
RedHill Biopharma Provides Update on Progress With RHB-104 Ongoing Phase III Program for Crohn's Disease Following FDA Meeting
GlobeNewswire - Thu Jan 29, 6:13AM CST
-- RedHill and Quest Diagnostics concluded a pre-submission meeting with U.S. FDA regarding RedHill's companion diagnostic test for the detection of MAP bacterium, an extension of RedHill's ongoing RHB-104 Phase III Crohn's disease development program
RDHL: 12.69 (+0.04), DGX: 71.68 (+0.03)
RedHill Biopharma to Present at the 17th Annual BIO CEO & Investor Conference
GlobeNewswire - Wed Jan 28, 7:10AM CST
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" , an Israeli biopharmaceutical company primarily focused on late clinical-stage, proprietary, orally-administered drugs for inflammatory and gastrointestinal diseases, including gastrointestinal cancers, today announced that Dror Ben-Asher, RedHill's Chief Executive Officer, will be presenting at the 17 Annual BIO CEO & Investor Conference on Monday, February 9, 2015, at 14:00 EST in the Park South room at the Waldorf Astoria in New York City.
RDHL: 12.69 (+0.04)
RedHill Biopharma to Present at Biotech Showcase(TM) 2015 Conference in San Francisco
GlobeNewswire - Fri Jan 09, 5:04AM CST
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" , an Israeli biopharmaceutical company primarily focused on late clinical-stage, proprietary, orally-administered drugs for inflammatory and gastrointestinal diseases, including gastrointestinal cancers, today announced that Adi Frish, RedHill's Senior VP Business Development and Licensing, will be presenting at Biotech Showcase 2015 Conference on Monday, January 12, 2015, at 14:00 PST in the Mission II room at the Parc 55 Wyndham San Francisco Union Square Hotel.
RDHL: 12.69 (+0.04)
RedHill Announces Milestones & Regulatory Events for 2015 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 06, 3:00PM CST
RedHill Biopharma Ltd. (RDHL) announced selected key milestones and regulatory updates expected in 2015.
RDHL: 12.69 (+0.04), SLXP: 152.35 (+3.17), SCMP: 15.32 (+0.04), BIOD: 1.38 (-0.14)
RedHill Bio provides outlook for 2015
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 6:48AM CST
RDHL: 12.69 (+0.04)
RedHill Biopharma Business Outlook and Anticipated Key Milestones for 2015
GlobeNewswire - Mon Jan 05, 6:00AM CST
Upcoming milestones include:
RDHL: 12.69 (+0.04)
RedHill's Bekinda Accepted for Review in the EU, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 02, 3:40PM CST
Shares of RedHill Biopharma Ltd. (RDHL) surged after the company announced that the UK Medicines and Healthcare Products Regulatory Agency has validated its Marketing Authorization Application for its pipeline candidate Bekinda.
RDHL: 12.69 (+0.04), SCMP: 15.32 (+0.04), GSK: 47.94 (+1.99), BIOD: 1.38 (-0.14)
Rewards Outweigh Risks: Research Reports on Walgreens, Tekmira, RedHill, Verso, and Pacific Ethanol
PR Newswire - Fri Jan 02, 6:40AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Walgreens (NASDAQ: WBA), Tekmira (NASDAQ: TKMR), RedHill (NASDAQ: RDHL), Verso (NYSE: VRS), and Pacific Ethanol (NASDAQ: PEIX). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
WBA: 78.73 (-1.23), RDHL: 12.69 (+0.04), VRS: 2.23 (unch), TKMR: 21.45 (-0.22), PEIX: 9.82 (+0.15)
RedHill's European MAA for Bekinda accepted
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 6:54AM CST
RDHL: 12.69 (+0.04)
RedHill Biopharma Announces Acceptance for Review of BEKINDA(TM) European Marketing Application for Oncology Support
GlobeNewswire - Wed Dec 31, 6:00AM CST
-- The UK MHRA has validated the European marketing application for the indications of chemotherapy and radiotherapy-induced nausea and vomiting; MHRA's feedback is expected during H2/2015
RDHL: 12.69 (+0.04)
RedHill Biopharma Acquires Technology from University of Minnesota as Part of Ongoing RHB-104 Phase III Crohn's Program
GlobeNewswire - Thu Dec 18, 5:05AM CST
-- The acquired diagnostic technology is intended for the detection of Mycobacterium avium subspecies paratuberculosis (MAP) bacterium; Increasing evidence supports the hypothesis that Crohn's disease is caused by MAP infection in susceptible patients
RDHL: 12.69 (+0.04), DGX: 71.68 (+0.03)
RedHill commences new Phase 3 Bekinda study in U.S.
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 8:03AM CST
RDHL: 12.69 (+0.04)
RedHill Biopharma Announces Closing of Public Offering of Its American Depository Shares
GlobeNewswire - Fri Feb 13, 9:19AM CST
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" or the "Company"
, an Israeli biopharmaceutical company primarily focused on late clinical-stage, proprietary, orally-administered drugs for inflammatory and gastrointestinal diseases, including gastrointestinal cancers, is today announcing the closing of its previously announced underwritten public offering of 1,000,000 American Depository Shares ("ADSs" , each representing ten of its ordinary shares, at an offering price of $12.50 per ADS. RedHill has also granted the underwriters a 30-day option to purchase up to 150,000 additional ADSs to cover over-allotments, if any. RDHL: 12.69 (+0.04)
RedHill Biopharma to Present at the Life Sciences Israel(TM) 2015 3rd Annual International Partnering Conference
GlobeNewswire - Thu Feb 12, 7:02AM CST
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"
, an Israeli biopharmaceutical company primarily focused on late clinical-stage, proprietary, orally-administered drugs for inflammatory and gastrointestinal diseases, including gastrointestinal cancers, today announced that Dror Ben-Asher, RedHill's Chief Executive Officer, will be presenting at the Life Sciences Israel 2015 3 Annual International Partnering Conference on Thursday, February 19, 2015, at 11:30am IST, at the Dan Panorama Hotel, in Tel-Aviv, Israel. RDHL: 12.69 (+0.04)
RedHill Bio prices offering
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 9:43AM CST
RDHL: 12.69 (+0.04)
RedHill Biopharma Prices Public Offering of Its American Depository Shares
GlobeNewswire - Tue Feb 10, 8:08AM CST
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" or the "Company"
, an Israeli biopharmaceutical company primarily focused on late clinical-stage, proprietary, orally-administered drugs for inflammatory and gastrointestinal diseases, including gastrointestinal cancers, today announced pricing of its previously announced underwritten public offering of 1 million American Depository Shares ("ADSs" , each representing ten of its ordinary shares, at an offering price of $12.5 per ADS. RDHL: 12.69 (+0.04)
17 Healthcare Companies To Consider Based On Patent Dynamics And IP/Patent Indexes
Innovalpha - Seeking Alpha - Tue Feb 10, 8:08AM CST
Introduction We will present here a few healthcare stocks that have been recently selected by our IP models. As already explained in our SA article " Patent Dynamics And Stock Performance ", Innovalpha has developed proprietary IP and...
SGYP: 2.98 (unch), INSM: 17.40 (+0.69), RNN: 0.75 (+0.01), ZSPH: 46.77 (+3.42), RDHL: 12.69 (+0.04), ASPX: 65.76 (+2.76), ACUR: 0.55 (+0.01), XNPT: 6.69 (-0.21), SPNC: 33.69 (-0.06), CORI: 7.00 (-0.05), SAGE: 41.03 (-0.07), EBIO: 10.13 (+0.05), HAE: 42.94 (-0.59), JAZZ: 169.69 (+6.89), ICPT: 209.12 (+7.12), NVDQ: 15.12 (+0.51)
RedHill Biopharma initiates equity offering
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 3:10PM CST
RDHL: 12.69 (+0.04)
RedHill Biopharma Announces Proposed Public Offering of Its American Depository Shares
GlobeNewswire - Mon Feb 09, 3:00PM CST
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" or the "Company"
, an Israeli biopharmaceutical company primarily focused on late clinical-stage, proprietary, orally-administered drugs for inflammatory and gastrointestinal diseases, including gastrointestinal cancers, today announced that it intends to offer its American Depository Shares ("ADSs" , each representing ten of its ordinary shares, in an underwritten public offering. RedHill also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the ADSs offered to the public to cover over-allotments, if any. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. RDHL: 12.69 (+0.04)
Global Migraine Drugs Market 2015-2019 with Abbott, Allergan, Eisai, Endo, GlaxoSmithKline, Impax Laboratories & Pfizer Dominating
M2 - Fri Feb 06, 8:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/s55lbq/global_migraine) has announced the addition of the "Global Migraine Drugs Market 2015-2019" report to their offering. The Global Migraine Drugs market to grow at a CAGR of 3.54% over the period 2014-2019. Migraine is a complex neurological medicial condition characterized by a severe headache. The headache is often accompanied by nausea, vomiting, and extreme sensitivity to light and sound. Given their hormonal fluctuation, women are more susceptible to have migraine than men. Anti-migraine drugs are the therapeutic agents to be used against migraine. Treatment includes painkillers, anti-inflammatory painkillers, anti-sickness medicines, and triptan medicines. The development of new drugs such as CGRP receptor antagonist and Botox is one of the major trends emerging in the market. Moreover, the demand for anti-migraine drugs is expected to grow further driving the market growth. According to the report, an increased prevalence of migraine is one of the main drivers of the market. Migraine is highly prevalent worldwide and affects people irrespective of their age, race, level of income, and geographical location. Further, the report states that the high cost of drugs is one of the main challenges faced by the market. Regardless of the numerous benefits, the high cost of drugs impedes acceptability among patients. The manufacturing process of a generic involves the use of the right equipment, expertise, and the ability to demonstrate to the FDA that the generic is absorbed through the skin in quantities that are identical to that of the branded drug. This cycle leads to an increase in the manufacturing costs, thereby increasing the overall cost of the drug. Key Vendors - Abbott - Allergan - Eisai - Endo - GlaxoSmithKline - Impax Laboratories - Pfizer Other Prominent Vendors - Almirall - Amgen - AstraZeneca - Boehringer Ingelheim - Eli Lilly - IntelGenx Technologies - Johnson & Johnson - Nautilus - OptiNose - RedHill Biopharma - Zogenix Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Migraine Pipeline Snapshot - Migraine Pipeline Assessment - Market Segmentation by Therapeutic Class - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/s5...l_migraine
IPXL: 39.51 (+0.69), AGN: 229.49 (+1.87), JNJ: 99.62 (+1.18), RDHL: 12.69 (+0.04), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99)
RedHill Biopharma Provides Update on Progress With RHB-104 Ongoing Phase III Program for Crohn's Disease Following FDA Meeting
GlobeNewswire - Thu Jan 29, 6:13AM CST
-- RedHill and Quest Diagnostics concluded a pre-submission meeting with U.S. FDA regarding RedHill's companion diagnostic test for the detection of MAP bacterium, an extension of RedHill's ongoing RHB-104 Phase III Crohn's disease development program
RDHL: 12.69 (+0.04), DGX: 71.68 (+0.03)
RedHill Biopharma to Present at the 17th Annual BIO CEO & Investor Conference
GlobeNewswire - Wed Jan 28, 7:10AM CST
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"
, an Israeli biopharmaceutical company primarily focused on late clinical-stage, proprietary, orally-administered drugs for inflammatory and gastrointestinal diseases, including gastrointestinal cancers, today announced that Dror Ben-Asher, RedHill's Chief Executive Officer, will be presenting at the 17 Annual BIO CEO & Investor Conference on Monday, February 9, 2015, at 14:00 EST in the Park South room at the Waldorf Astoria in New York City. RDHL: 12.69 (+0.04)
RedHill Biopharma to Present at Biotech Showcase(TM) 2015 Conference in San Francisco
GlobeNewswire - Fri Jan 09, 5:04AM CST
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"
, an Israeli biopharmaceutical company primarily focused on late clinical-stage, proprietary, orally-administered drugs for inflammatory and gastrointestinal diseases, including gastrointestinal cancers, today announced that Adi Frish, RedHill's Senior VP Business Development and Licensing, will be presenting at Biotech Showcase 2015 Conference on Monday, January 12, 2015, at 14:00 PST in the Mission II room at the Parc 55 Wyndham San Francisco Union Square Hotel. RDHL: 12.69 (+0.04)
RedHill Announces Milestones & Regulatory Events for 2015 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 06, 3:00PM CST
RedHill Biopharma Ltd. (RDHL) announced selected key milestones and regulatory updates expected in 2015.
RDHL: 12.69 (+0.04), SLXP: 152.35 (+3.17), SCMP: 15.32 (+0.04), BIOD: 1.38 (-0.14)
RedHill Bio provides outlook for 2015
Seeking Alpha - at Seeking Alpha - Mon Jan 05, 6:48AM CST
RDHL: 12.69 (+0.04)
RedHill Biopharma Business Outlook and Anticipated Key Milestones for 2015
GlobeNewswire - Mon Jan 05, 6:00AM CST
Upcoming milestones include:
RDHL: 12.69 (+0.04)
RedHill's Bekinda Accepted for Review in the EU, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 02, 3:40PM CST
Shares of RedHill Biopharma Ltd. (RDHL) surged after the company announced that the UK Medicines and Healthcare Products Regulatory Agency has validated its Marketing Authorization Application for its pipeline candidate Bekinda.
RDHL: 12.69 (+0.04), SCMP: 15.32 (+0.04), GSK: 47.94 (+1.99), BIOD: 1.38 (-0.14)
Rewards Outweigh Risks: Research Reports on Walgreens, Tekmira, RedHill, Verso, and Pacific Ethanol
PR Newswire - Fri Jan 02, 6:40AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Walgreens (NASDAQ: WBA), Tekmira (NASDAQ: TKMR), RedHill (NASDAQ: RDHL), Verso (NYSE: VRS), and Pacific Ethanol (NASDAQ: PEIX). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
WBA: 78.73 (-1.23), RDHL: 12.69 (+0.04), VRS: 2.23 (unch), TKMR: 21.45 (-0.22), PEIX: 9.82 (+0.15)
RedHill's European MAA for Bekinda accepted
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 6:54AM CST
RDHL: 12.69 (+0.04)
RedHill Biopharma Announces Acceptance for Review of BEKINDA(TM) European Marketing Application for Oncology Support
GlobeNewswire - Wed Dec 31, 6:00AM CST
-- The UK MHRA has validated the European marketing application for the indications of chemotherapy and radiotherapy-induced nausea and vomiting; MHRA's feedback is expected during H2/2015
RDHL: 12.69 (+0.04)
RedHill Biopharma Acquires Technology from University of Minnesota as Part of Ongoing RHB-104 Phase III Crohn's Program
GlobeNewswire - Thu Dec 18, 5:05AM CST
-- The acquired diagnostic technology is intended for the detection of Mycobacterium avium subspecies paratuberculosis (MAP) bacterium; Increasing evidence supports the hypothesis that Crohn's disease is caused by MAP infection in susceptible patients
RDHL: 12.69 (+0.04), DGX: 71.68 (+0.03)
RedHill commences new Phase 3 Bekinda study in U.S.
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 8:03AM CST
RDHL: 12.69 (+0.04)
